Although the precise function and physiological role of this gene is unknown, the fact that it is a cell surface antigen that is highly expressed in different carcinomas and expressed at relatively low levels (if at all) in many normal tissues has led to its evaluation as a candidate therapeutic target for radioimmunotherapy treatment, particularly for breast cancer[28]. This evidence concerns the gene CD53 and breast carcinoma.